- Interpretable dimensionality reduction of single cell transcriptome data with deep generative models.
- The RNA-binding protein YBX1 regulates epidermal progenitors at a posttranscriptional level.
- Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
- Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation.
Dr. Samuel Aparicio named co-lead of new Stand Up to Cancer Canada – Canadian Breast Cancer Foundation Dream Team
October 1, 2015
Dr. Samuel Aparicio named co-lead of new Stand Up to Cancer Canada – Canadian Breast Cancer Foundation Dream Team By: Jenn Currie, Communications Officer, BC Cancer Agency published on: 10/1/2015 Congratulations to our very own Dr. Samuel Aparicio who was recently named co-lead of the Stand Up to Cancer Canada—Canadian Breast Cancer Foundation Dream Team! […]
May 11, 2015
Research published today by scientists at the BC Cancer Agency in Cancer Cell brings new hope for the treatment of high-risk childhood sarcomas – a type of cancer that has seen almost no treatment improvement in the last 20 years in spite of intense research efforts. Sarcomas are malignant – meaning they are cancerous – […]
February 17, 2015
NSERC Brockhouse Prize For CycloMed99 17 February 2015 For their outstanding teamwork in realizing a solution for safe and reliable isotope production for hospitals in Canada, interdisciplinary research team CycloMed99 will be receiving a prestigious national award at a ceremony in Ottawa today. The Honourable David Johnston, Governor General of Canada, will present the NSERC Brockhouse Canada […]
Posted in Benard Lab, Media, News And Events | Tagged with BC Cancer Agency, BCCA, BCCRC, Benard, Brockhouse Prize, Cancer Research, Cyclotron, Francois Benard, Media, Medical Isotopes, NSERC, Radiology, Research, TRIUMF, UBC
BC Cancer Agency scientists make internationally significant discovery, mapping the evolution of breast cancer ‘avatars’
December 1, 2014
Vancouver – A just-published paper in the prestigious journal Nature highlights how researchers at the BC Cancer Agency are using human breast cancer ‘avatars’ — models of human breast cancers — to measure how complex cancers develop and change over time. The research is unprecedented because it uses single cancer cells to expose how breast […]
November 10, 2014
Dr. Samuel Aparicio, 2014 Aubrey J. Tingle Prize recipient (photo: CNW Group/Canadian Cancer Society (National Office)) Breast cancer researcher Dr. Samuel Aparicio has been named the winner of the fifth annual Aubrey J. Tingle Prize. Created in honour of MSFHR’s founding president & CEO, this award is given to a British Columbia researcher whose work […]
April 11, 2013
From the Vancouver Province By Mike Raptis The Province April 7, 2013 A group of Vancouver researchers will be playing a central role in a newly-formed international “pediatric cancer dream team.” The announcement came Sunday during the 2013 annual meeting of the St. Baldrick’s Foundation at the American Association for Cancer Research in Washington, D.C. The […]
February 26, 2013
Outsmarting breast cancer, one cell at a time With a $1.25 million grant from the Canadian Cancer Society, Dr Sam Aparicio and his team will answer questions about how breast cancer arises, grows and mutates. The researchers will use sophisticated techniques to analyze DNA from individual breast cancer cells and then observe how the cells […]
December 28, 2011
Dr. David Huntsman and colleagues, including Drs. Aparicio, Sorensen and Shah, have identified mutations in a gene called DICER in rare, seemingly unrelated ovarian, uterine, and testicular cancers. When the group began sequencing the genomes of these and other rare tumours, they expected to find different gene mutations in each form of the disease. However, […]
Posted in Aparicio Lab, Media, News And Events, Papers, Shah Lab, Sorensen Lab | Tagged with Aparicio, BCCF, BCCRC, Cancer, CIHR, Genome BC, GSC, Huntsman, Morin, MSFHR, NEJM, Research, Shah, Sorensen, UBC
November 28, 2009
The world is facing a shortage of the key medical isotope Technetium-99m (Tc-99m). More than 80% of the estimated 1.5 million nuclear medicine procedures performed annually in Canada use radiopharmaceuticals based on this isotope, which is currently produced using nuclear reactors. Together with TRIUMF and other partners, the BC Cancer Agency (BCCA) has received a […]